RARX - Ra Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 51.52B
Enterprise Value 31.23B
Trailing P/E N/A
Forward P/E 1-15.19
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)609.00
Price/Book (mrq)7.95
Enterprise Value/Revenue 3492.75
Enterprise Value/EBITDA 6-18.11

Trading Information

Stock Price History

Beta (3Y Monthly) 1.22
52-Week Change 3207.61%
S&P500 52-Week Change 35.54%
52 Week High 336.25
52 Week Low 38.67
50-Day Moving Average 327.64
200-Day Moving Average 323.43

Share Statistics

Avg Vol (3 month) 3438.01k
Avg Vol (10 day) 3322.4k
Shares Outstanding 542.3M
Float 31.03M
% Held by Insiders 14.47%
% Held by Institutions 192.70%
Shares Short (Jun 28, 2019) 42.59M
Short Ratio (Jun 28, 2019) 44.68
Short % of Float (Jun 28, 2019) 410.06%
Short % of Shares Outstanding (Jun 28, 2019) 46.12%
Shares Short (prior month May 31, 2019) 42.34M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-2,790.12%

Management Effectiveness

Return on Assets (ttm)-26.97%
Return on Equity (ttm)-45.00%

Income Statement

Revenue (ttm)2.5M
Revenue Per Share (ttm)0.07
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)2.5M
EBITDA -68.01M
Net Income Avi to Common (ttm)-67.48M
Diluted EPS (ttm)-1.91
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)191.65M
Total Cash Per Share (mrq)4.53
Total Debt (mrq)5.11M
Total Debt/Equity (mrq)2.67
Current Ratio (mrq)20.10
Book Value Per Share (mrq)4.53

Cash Flow Statement

Operating Cash Flow (ttm)-57.45M
Levered Free Cash Flow (ttm)-35.12M